1. Bu, Liang, Jiang, Guanchao, Yang, Fan, Liu, Jun, Wang, Jun. 2011. Highly expressed SLC35F2 in non-small cell lung cancer is associated with pathological staging. In Molecular medicine reports, 4, 1289-93. doi:10.3892/mmr.2011.572. https://pubmed.ncbi.nlm.nih.gov/21874247/
2. Chen, Mei, Gao, Xin, Huang, Denggao, Cao, Hui, Zhang, Shufang. 2019. Knockdown of SLC35F2 Inhibits the Proliferation and Metastasis of Bladder Cancer Cells. In OncoTargets and therapy, 12, 10771-10786. doi:10.2147/OTT.S229332. https://pubmed.ncbi.nlm.nih.gov/31849485/
3. Chandrasekaran, Arun Pandian, Kaushal, Kamini, Park, Chang-Hwan, Kim, Kye-Seong, Ramakrishna, Suresh. 2021. USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2. In Theranostics, 11, 9752-9771. doi:10.7150/thno.63806. https://pubmed.ncbi.nlm.nih.gov/34815782/
4. He, Jing, Jin, Yiting, Zhou, Mingxia, Liu, Xiuping, Zou, Qiang. 2018. Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor-β type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis. In Cancer science, 109, 642-655. doi:10.1111/cas.13478. https://pubmed.ncbi.nlm.nih.gov/29274137/
5. Nyquist, Michael D, Corella, Alexandra, Burns, John, Nelson, Peter S, Mostaghel, Elahe A. . Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. In Molecular cancer research : MCR, 15, 521-531. doi:10.1158/1541-7786.MCR-16-0315-T. https://pubmed.ncbi.nlm.nih.gov/28465296/
智鼠故事 
